AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00619840
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
Trial: NCT02292706
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure of interest for participants who received LDV/SOF in a previous Gilead study for chronic HCV infection.
Trial: NCT02292706
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure of interest for participants who received SOF/VEL in a previous Gilead study for chronic HCV infection.
Trial: NCT01864057
Drug: thiamine hydrochloride 100 mg
RxNorm normalized name: thiamine hydrochloride 100 MG
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01893125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02292706
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure of interest for participants who received SOF/VEL/VOX in a previous Gilead study for chronic HCV infection.
Trial: NCT04433585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01633983
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 7.5 mg per week p.o. escalating up to 15 mg per week
Trial: NCT01633983
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5 mg per week per os escalating to 15 mg per week
Trial: NCT02501798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo
Trial: NCT03085030
Drug: Antioxidant Formula
RxNorm normalized name: Antioxidant Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant tablet will be taken by the patients
Trial: NCT03085030
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be taken by the patients
Trial: NCT02292706
Drug: Other SOF-Based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The other SOF-based regimens may have included the following:~* BMS-790052 (Daclatasvir) + GS-7977 (SOF) with or without RBV~* LDV/SOF + GS-9669, GS-7977 (SOF) + with or without RBV + TMC-435 (Simeprevir)~* LDV/SOF + Vedroprevir (VDV), LDV/SOF + GS-9669 (250 mg and 500 mg)~* LDV/SOF + VDV + RBV~* Simeprevir + SOF~* TMC-435 (Simeprevir) + VEL/SOF
Trial: NCT02742909
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline as a placebo was administered as a continuous infusion for 24 hours
Trial: NCT00292162
Drug: Aldosterone Antagonists - spironolactone
RxNorm normalized name: Aldosterone antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
Trial: NCT00738530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV every 2 weeks
Trial: NCT00938470
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00938470
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02394951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical, matching inactive substance
Trial: NCT04179461
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration
Trial: NCT04179461
Drug: emollient cream
RxNorm normalized name: EMOLLIENT CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT00558259
Drug: matching placebo twice daily (BID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo BID
Trial: NCT00183430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules are taken orally twice per day at 10 am and bedtime.
Trial: NCT04179461
Drug: Asthma Controller Medication
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
Trial: NCT03885973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented milk containing placebo for three weeks
Trial: NCT03895801
Drug: Placebo-IFX-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenously administered
Trial: NCT03895801
Drug: Placebo-Glucocorticoid (Placebo-GC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered
Trial: NCT03175211
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02207881
Drug: VDO gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VDO gel
Trial: NCT02207881
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo gel
Trial: NCT01666379
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01000870
Drug: MNI-513-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
Trial: NCT02952378
Drug: Albumins
RxNorm normalized name: lactalbumins, hydrolyzates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
Trial: NCT00728611
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physiological water 3cc + lidocain 3cc
Trial: NCT01559753
Drug: compare 8 to15 days of antibiotic treatment
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.~•~Beta-Lactams:~* Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS~* Ceftriaxone : 2 g OD during 3 days, then 1 g OD~* Cefotaxime : 2 g TDS during 3 days, then 1 g TDS~Aminoglycosides~* Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)~* Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)~* Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Trial: NCT02267356
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01957410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
Trial: NCT04037618
Drug: [14C]-EYP001a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drinking suspension
Trial: NCT01830959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one a day
Trial: NCT04256629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will receive oral dose of placebo
Trial: NCT02669849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02719977
Drug: CX5461
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03281044
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
Trial: NCT01452659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
Trial: NCT01847469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01889160
Drug: AZD4721 Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-9 mg/mL liquid solution
Trial: NCT01889160
Drug: AZD4721 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid solution
Trial: NCT01347762
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo capsule by mouth twice daily
Trial: NCT02038543
Drug: Hydroxyproline and Leucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
Trial: NCT02372656
Drug: 1.2% Simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
Trial: NCT03018054
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily administration
Trial: NCT01170585
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
Trial: NCT01170585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01889160
Drug: AZD4721 Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/g liquid suspension
Trial: NCT03168607
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
Trial: NCT03712280
Drug: MNK6106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gram tablet of MNK6106 for oral administration
Trial: NCT02021097
Drug: Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, orally, opd
Trial: NCT02021097
Drug: Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, orally, opd
Trial: NCT01947985
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
Trial: NCT02461693
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg delivered as pill; one-time dose
Trial: NCT02461693
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose-based pill; one-time dose
Trial: NCT00915070
Drug: Physiological saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion period 60 minutes
Trial: NCT00945646
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill four times two times a day
Trial: NCT02285465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01066234
Drug: chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
Trial: NCT01688583
Drug: Fentanyl matrix
RxNorm normalized name: FentaNYL Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
Trial: NCT04315051
Drug: Cohort 1 J. Lividum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject to apply DBI-001 Gel on each foot covering all web spaces, the plantar and lateral aspects, toes and toenails
Trial: NCT01873014
Drug: chinese herbs-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two agent per day, twice a day
Trial: NCT01873014
Drug: chinese herbs-II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two agent per day, twice a day
Trial: NCT00187447
Drug: indomethacin (two different dosing regimens)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00733967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo capsules as control.
Trial: NCT02172976
Drug: Natriumfolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03108482
Drug: Celecoxib (Celebrex®)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
Trial: NCT03108482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
Trial: NCT02051296
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RCT blinded placebo trial
Trial: NCT02051296
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCT blinded placebo trial
Trial: NCT01893606
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00975416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given in the context of cognitive behavioral therapy
Trial: NCT04206865
Drug: Standard Oral Vasodilators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient's will be randomized to ICU initiation of sacubitril-valsartan vs. alternate oral vasodilator therapy in 1:1 fashion. Alternate vasodilators will include ARBs, hydralazine and isosorbide dinitrate, and ACEi
Trial: NCT03750773
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject is given a Placebo capsule every 8 hours x 48 hours postoperatively for pain control.
Trial: NCT02483585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once a month by subcutaneous injection
Trial: NCT00527085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Trial: NCT00825916
Drug: AZX100 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Trial: NCT00526305
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10 mg ,15 mg or 20 mg depending of age
Trial: NCT00526305
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
Trial: NCT00526305
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 day, i.v., days 1 to 15 in consolidation
Trial: NCT00825916
Drug: AZX100 Drug Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Trial: NCT04569214
Drug: PAZ320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment arm B - 2 tablets of PAZ320 and 2 tablets of placebo, total of 4 tablets Treatment arm C - 4 tablets of PAZ320
Trial: NCT00825916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
Trial: NCT02423018
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
Trial: NCT03434678
Drug: Propofol+ Rocuronium+ Fentanyl + Inhalational
RxNorm normalized name: fentanyl Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will have the standard intraoperative management during surgery and have the epidural started just before being taken to the recovery room.
Trial: NCT02181205
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00699920
Drug: Coarsucam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
Trial: NCT00392990
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
Trial: NCT01253980
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days
Trial: NCT00648154
Drug: Femara® Tablets 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5mg, single dose fed
Trial: NCT01515397
Drug: Gelofusine balanced
RxNorm normalized name: Gelofusine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine balanced combined with Sterofundin ISO
Trial: NCT01515397
Drug: Gelofusine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine 4% combined with NaCl 0.9%
Trial: NCT00513604
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously 60 mg/kg/day, day -7 to -6
Trial: NCT00447915
Drug: ibandronic acid 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg(i.v.)/month for 35 months
Trial: NCT00447915
Drug: RIS placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg(p.o.)/day for 36 months
Trial: NCT00447915
Drug: 1.0mg ibandronic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg(i.v.)/month for 35 months
Trial: NCT00447915
Drug: ibandronic acid placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg(i.v.)/month for 35 months
Trial: NCT00447915
Drug: 2.5mg RIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg(p.o.)/day for 36 months
Trial: NCT04044079
Drug: Dinoprostone
RxNorm normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT04044079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Trial: NCT00565318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x 1 film coated tablet daily. Duration: 12 weeks.
Trial: NCT03426345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injected subcutaneously twice daily.
Trial: NCT01149941
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Trial: NCT03587077
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal application
Trial: NCT00950950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT00666393
Drug: fentanyl iontophoretic transdermal system (40mcg) No placebo
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
Trial: NCT00666393
Drug: fentanyl iontophoretic transdermal system (40mcg)
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours